Exelixis, Inc. - Common Stock (NQ:EXEL)

64.58 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

October 15, 2026

From Exelixis, Inc.

Via Business Wire

Exelixis (NASDAQ:EXEL): A Quality Stock With Durable Returns on Capital ↗

October 12, 2026

Via Chartmill

Exelixis (NASDAQ:EXEL) Flashes Strong Technicals and Tight Breakout Setup ↗

October 05, 2026

Via Chartmill

Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B ↗

September 17, 2026

Exelixis (NASDAQ:EXEL) President and CEO Michael Morrissey said the company is focused on expanding its oncology franchises through internal development, selective business development and potential...

Via MarketBeat

Topics Artificial Intelligence

Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle ↗

September 15, 2026

Exelixis (NASDAQ:EXEL) executives outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib, or zanza, in colorectal cancer later this year....

Via MarketBeat

Exelixis (NASDAQ:EXEL): A Value Stock Backed by Strong Fundamentals ↗

August 22, 2026

Via Chartmill

Exelixis (NASDAQ:EXEL) Shows Strong Breakout Setup with Perfect Technical Rating ↗

August 06, 2026

Via Chartmill

Exelixis (NASDAQ:EXEL) Posts Mixed Q2: EPS Beats, Revenue Misses, Guidance Lowered ↗

August 05, 2026

Via Chartmill

Exelixis Inc. (NASDAQ:EXEL): A Decent Value Play in the Biotechnology Sector ↗

July 01, 2026

Via Chartmill

Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises ↗

September 14, 2026

Exelixis (NASDAQ:EXEL) executives outlined a franchise-focused growth strategy centered on expanding CABOMETYX across renal cell carcinoma and neuroendocrine tumors while advancing zanzalintinib...

Via MarketBeat

Topics Artificial Intelligence

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

September 01, 2026

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories

August 31, 2026

From Exelixis, Inc.

Via Business Wire

Exelixis Inc (NASDAQ:EXEL) Offers Decent Value with Strong Profitability and Financial Health ↗

June 09, 2026

Via Chartmill

EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law

August 16, 2026

From Schall, Brown & Schwartz LLP

Via Business Wire

Exelixis (EXEL) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

Cabozantinib revenue grew 10%, while zanzalintinib advances toward FDA decision in December.

Via The Motley Fool

Topics Earnings

EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL)

August 12, 2026

From Levi & Korsinsky, LLP

Via Business Wire

Exelixis Q2 Earnings Call Highlights ↗

August 05, 2026

Exelixis (NASDAQ:EXEL) reported second-quarter 2026 revenue of approximately $629 million, including $573 million in cabozantinib franchise net product revenue, as the company prepared for a potential...

Via MarketBeat

Topics Earnings

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

August 05, 2026

From Exelixis, Inc.

Via Business Wire

These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead ↗

July 24, 2026

They are riding strong tailwinds that could lift them higher.

Via The Motley Fool

Topics Economy

Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026

July 22, 2026

From Exelixis, Inc.

Via Business Wire

3 Under-the-Radar Stocks to Buy and Hold ↗

July 10, 2026

Sometimes, little-known stocks are worth buying.

Via The Motley Fool

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

June 22, 2026

From Exelixis, Inc.

Via Business Wire

What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗

May 30, 2026

Ultragenyx develops therapies for rare genetic diseases, with a portfolio spanning approved biologics and a pipeline of gene therapies.

Via The Motley Fool

Topics Regulatory Compliance

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

May 30, 2026

From Exelixis, Inc.

Via Business Wire

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

May 27, 2026

From Exelixis, Inc.

Via Business Wire

Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near ↗

May 23, 2026

Exelixis (NASDAQ:EXEL) remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company’s senior vice president...

Via MarketBeat

Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types

May 21, 2026

From Exelixis, Inc.

Via Business Wire

GlobeFlex Exits NCR Atleos After Brink’s Buyout Deal ↗

May 20, 2026

NCR Atleos delivers self-service banking technology and managed services to financial institutions and enterprise clients worldwide.

Via The Motley Fool

Topics Regulatory Compliance

Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer

May 19, 2026

From Exelixis, Inc.

Via Business Wire

Prediction: This Stock Could Double By 2031 ↗

May 15, 2026

It's not the most prominent company in its industry, but it is definitely worth a second look.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.